News & Articles

A protein long studied for its connection to aging may also play a key role in protecting the body from chronic disease, according to new research from the laboratory of Mikhail Kolonin, PhD, published in Aging Cell.

Three UTHealth Houston researchers received more than $6 million in CPRIT grants to advance cancer research, treatment, and prevention.

UTHealth Houston has announced the establishment of the Department of Cardiology at McGovern Medical School, marking a significant milestone in the university’s efforts to advance cardiovascular care, research, and education across the region. The new department, led by founding chair Biswajit Kar, MD, becomes the school’s 24th academic department and reflects the continued growth and national distinction of UTHealth Houston’s cardiovascular programs.

A peptide that successfully targeted and killed metastatic cancer cells in mice may open the door to developing more efficient ways to detect and treat metastatic breast cancer in humans, UTHealth Houston researchers have discovered. 

Pancreatic cancer remains one of the most difficult cancers to treat, in large part because tumors do not exist in isolation. Instead, they are surrounded by a dense and complex network of blood vessels, connective tissue, and immune cells that shape how the disease grows and responds to therapy.

Researchers at UTHealth Houston have been awarded a three-year, $7.8 million grant from the Aligning Science Across Parkinson’s initiative to support projects that will help health professionals better understand how Parkinson’s disease occurs in the brain. 

UTHealth Houston has become the first health center in Texas to offer Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT, an FDA-approved form of transcranial magnetic stimulation for treatment-resistant depression. 

A new multidisciplinary center at McGovern Medical School at UTHealth Houston is bringing together experts across medicine, science, and engineering to transform how congenital heart disease is understood and treated across a patient’s lifetime.

CrossBridge Bio, a biotechnology company developing next-generation antibody-drug conjugates based on discoveries by researchers at UTHealth Houston, is taking a major step toward clinical translation after being acquired by Eli Lilly.

The risk of Alzheimer’s disease significantly decreases in older adults who receive a higher dose of the influenza vaccine compared to the standard dose, according to new research led by UTHealth Houston.